JP2023551943A5 - - Google Patents
Info
- Publication number
- JP2023551943A5 JP2023551943A5 JP2023533801A JP2023533801A JP2023551943A5 JP 2023551943 A5 JP2023551943 A5 JP 2023551943A5 JP 2023533801 A JP2023533801 A JP 2023533801A JP 2023533801 A JP2023533801 A JP 2023533801A JP 2023551943 A5 JP2023551943 A5 JP 2023551943A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- compound
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121513P | 2020-12-04 | 2020-12-04 | |
| US202063121508P | 2020-12-04 | 2020-12-04 | |
| US63/121,513 | 2020-12-04 | ||
| US63/121,508 | 2020-12-04 | ||
| PCT/IB2021/061268 WO2022118264A1 (en) | 2020-12-04 | 2021-12-03 | Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551943A JP2023551943A (ja) | 2023-12-13 |
| JP2023551943A5 true JP2023551943A5 (https=) | 2024-12-10 |
Family
ID=78844691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533801A Pending JP2023551943A (ja) | 2020-12-04 | 2021-12-03 | うつ病の処置のためのｎｒ２ｂ－ｎｍｄａ受容体ｎａｍについての投薬レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240041853A1 (https=) |
| EP (1) | EP4255419A1 (https=) |
| JP (1) | JP2023551943A (https=) |
| KR (1) | KR20230116865A (https=) |
| AU (1) | AU2021390209A1 (https=) |
| CA (1) | CA3203144A1 (https=) |
| IL (1) | IL303357A (https=) |
| MX (1) | MX2023006567A (https=) |
| TW (1) | TW202237103A (https=) |
| WO (1) | WO2022118264A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3258070A1 (en) * | 2022-06-02 | 2023-12-07 | Novartis Ag | SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS INTENDED FOR USE IN THE TREATMENT OF DEPRESSIVE DISORDERS |
| TW202539663A (zh) * | 2023-12-06 | 2025-10-16 | 瑞士商諾華公司 | 用於治療抑鬱障礙之組成物和方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| AR097794A1 (es) * | 2013-09-26 | 2016-04-13 | Mnemosyne Pharmaceuticals Inc | Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b |
| JO3579B1 (ar) * | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| US10202363B2 (en) * | 2014-12-23 | 2019-02-12 | Cerecor, Inc. | Compounds, compositions and methods |
| BR112018007181A2 (pt) * | 2015-10-14 | 2018-10-16 | Bristol-Myers Squibb Company | antagonistas de nr2b seletivos |
| KR20180063306A (ko) * | 2015-10-14 | 2018-06-11 | 브리스톨-마이어스 스큅 컴퍼니 | 선택적 nr2b 길항제 |
-
2021
- 2021-12-03 US US18/255,423 patent/US20240041853A1/en active Pending
- 2021-12-03 TW TW110145295A patent/TW202237103A/zh unknown
- 2021-12-03 IL IL303357A patent/IL303357A/en unknown
- 2021-12-03 WO PCT/IB2021/061268 patent/WO2022118264A1/en not_active Ceased
- 2021-12-03 KR KR1020237021993A patent/KR20230116865A/ko active Pending
- 2021-12-03 AU AU2021390209A patent/AU2021390209A1/en not_active Abandoned
- 2021-12-03 CA CA3203144A patent/CA3203144A1/en active Pending
- 2021-12-03 JP JP2023533801A patent/JP2023551943A/ja active Pending
- 2021-12-03 EP EP21824044.8A patent/EP4255419A1/en active Pending
- 2021-12-03 MX MX2023006567A patent/MX2023006567A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020033360A5 (https=) | ||
| JP2015526458A5 (https=) | ||
| EP4233861A3 (en) | Compositions for treatment of essential tremor | |
| JP2023551943A5 (https=) | ||
| JP2020073549A (ja) | パーキンソン病の処置に伴う運動不全及び運動障害副作用の処置 | |
| JP2021527050A5 (https=) | ||
| JP2018507243A5 (https=) | ||
| JP2017501154A5 (https=) | ||
| EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
| JP2022554276A5 (https=) | ||
| BR112022013264A2 (pt) | Combinação de formas de dosagem oral sólida de decitabina e cedazuridina | |
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| JP2019524888A5 (https=) | ||
| JP2021004249A5 (https=) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| JP2019507786A5 (https=) | ||
| JP2021535163A5 (https=) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| Zoe et al. | High-dose clonidine in a case of restless legs syndrome | |
| ES2275619T3 (es) | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. | |
| JP2005529152A5 (https=) | ||
| RU2018144248A (ru) | Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта | |
| Thongim et al. | Contemporary trends in dental local anaesthesia: a review of literature | |
| DE602006009976D1 (de) | Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung | |
| TR201004720T1 (tr) | Majör depresif bozukluğun tedavisi için o-desmetil venlafaksin |